Despite the emergence of risk-sharing agreements and prevalence of discounting, international reference pricing (IRP) remains at the center of pharmaceutical price controls across many countries worldwide. Growing in use among emerging markets, and still undergoing reforms in mature ones, IRP continues to make it difficult to optimize launch strategy, plan for price erosion, and assess whether fair prices are being set.

Drawing on primary research with payers and pharmaceutical companies, the International Reference Pricing Guidebook, 2017 Edition, covers 62 country profiles, a deep dive into the GCC region, analysis of potential reforms in China, and interviews with payers and KOLs.

Utilize the study to understand how IRP is used in practice, including how different product parameters (e.g. pack size, strength, formulation) are handled and may impact your strategy.